125 related articles for article (PubMed ID: 20433219)
1. It depends on what "mean" means: averaging versus event patterning in analyses of administrative claims data.
Fairman KA; Curtiss FR
J Manag Care Pharm; 2010 May; 16(4):288-91. PubMed ID: 20433219
[No Abstract] [Full Text] [Related]
2. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
3. Cost variation in diabetes care delivered in English hospitals.
Kristensen T; Laudicella M; Ejersted C; Street A
Diabet Med; 2010 Aug; 27(8):949-57. PubMed ID: 20653754
[TBL] [Abstract][Full Text] [Related]
4. Hospitalization costs for heart failure in people with type 2 diabetes: cost-effectiveness of its prevention measured by a simulated preventive treatment.
Caporale JE; Elgart J; Pfirter G; Martínez P; Viñes G; Insúa JT; Gagliardino JJ
Value Health; 2011; 14(5 Suppl 1):S20-3. PubMed ID: 21839892
[TBL] [Abstract][Full Text] [Related]
5. Epidemiological trends and direct costs of diabetes in a Northern Italy area: 2012 health administrative records analysis LHT n. 20 Verona.
Demurtas J; Alba N; Rigon G; Nesoti MV; Bovo C; Vaona A
Prim Care Diabetes; 2017 Dec; 11(6):570-576. PubMed ID: 28663023
[TBL] [Abstract][Full Text] [Related]
6. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
Levin PA; Zhou S; Gill J; Wei W
J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
[TBL] [Abstract][Full Text] [Related]
7. Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States.
Aagren M; Luo W
J Med Econ; 2011; 14(1):108-14. PubMed ID: 21241161
[TBL] [Abstract][Full Text] [Related]
8. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
9. [Costs of therapy of insulin-treated patients with Diabetes mellitus in Germany. Results of the JEVIN trial].
Schiel R; Müller UA; Stein G
Med Klin (Munich); 2005 Aug; 100(8):453-61. PubMed ID: 16096726
[TBL] [Abstract][Full Text] [Related]
10. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
11. Hemoglobin A1c in hemodialysis patients: should one size fit all?
Ix JH
Clin J Am Soc Nephrol; 2010 Sep; 5(9):1539-41. PubMed ID: 20671219
[No Abstract] [Full Text] [Related]
12. Standards of medical care for diabetic patients: a panel discussion.
Quevedo SF; Kahn CB; Wachtel TJ
R I Med J (1976); 1990 Sep; 73(9):421-8. PubMed ID: 2120766
[No Abstract] [Full Text] [Related]
13. Clinical effectiveness and cost savings in diabetes care, supported by pharmacist counselling.
Rodriguez de Bittner M; Chirikov VV; Breunig IM; Zaghab RW; Shaya FT
J Am Pharm Assoc (2003); 2017; 57(1):102-108.e4. PubMed ID: 27769877
[TBL] [Abstract][Full Text] [Related]
14. Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States.
Minshall ME; Roze S; Palmer AJ; Valentine WJ; Foos V; Ray J; Graham C
Clin Ther; 2005 Jun; 27(6):940-50. PubMed ID: 16117994
[TBL] [Abstract][Full Text] [Related]
15. Use of HbA1c in clinical practice: New insights.
Bloomgarden Z
J Diabetes; 2021 Apr; 13(4):280-281. PubMed ID: 33427383
[No Abstract] [Full Text] [Related]
16. Impact and duration effect of telemonitoring on ΗbA1c, BMI and cost in insulin-treated Diabetes Mellitus patients with inadequate glycemic control: A randomized controlled study.
Fountoulakis S; Papanastasiou L; Gryparis A; Markou A; Piaditis G
Hormones (Athens); 2015; 14(4):632-43. PubMed ID: 26188234
[TBL] [Abstract][Full Text] [Related]
17. Diabetes study findings: what do they mean?
Kaufman FR
School Nurse News; 2009 Sep; 26(4):10-1. PubMed ID: 19791478
[No Abstract] [Full Text] [Related]
18. Estimated Cost-Effectiveness, Cost Benefit, and Risk Reduction Associated with an Endocrinologist-Pharmacist Diabetes Intense Medical Management "Tune-Up" Clinic.
Hirsch JD; Bounthavong M; Arjmand A; Ha DR; Cadiz CL; Zimmerman A; Ourth H; Morreale AP; Edelman SV; Morello CM
J Manag Care Spec Pharm; 2017 Mar; 23(3):318-326. PubMed ID: 28230459
[TBL] [Abstract][Full Text] [Related]
19. Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit.
Baxter M; Hudson R; Mahon J; Bartlett C; Samyshkin Y; Alexiou D; Hex N
Diabet Med; 2016 Nov; 33(11):1575-1581. PubMed ID: 26773733
[TBL] [Abstract][Full Text] [Related]
20. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes.
Orzeck EA; Shi N; Blumentals WA
Clin Ther; 2007 Oct; 29(10):2246-55. PubMed ID: 18042482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
